Adamis Pharmaceuticals Corp (NASDAQ:ADMP)‘s stock had its “buy” rating reaffirmed by B. Riley in a note issued to investors on Wednesday. They presently have a $9.50 target price on the specialty pharmaceutical company’s stock. B. Riley’s target price points to a potential upside of 76.74% from the stock’s previous close.

Several other research analysts have also commented on the company. ValuEngine lowered Adamis Pharmaceuticals Corp from a “hold” rating to a “sell” rating in a research report on Tuesday. Raymond James Financial, Inc. assumed coverage on Adamis Pharmaceuticals Corp in a research report on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 price target for the company. Finally, Maxim Group reiterated a “buy” rating and issued a $13.00 price target on shares of Adamis Pharmaceuticals Corp in a research report on Monday, August 21st.

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) opened at 5.375 on Wednesday. The stock has a 50 day moving average price of $5.25 and a 200-day moving average price of $4.66. The stock’s market capitalization is $168.51 million. Adamis Pharmaceuticals Corp has a 12-month low of $2.40 and a 12-month high of $6.45.

COPYRIGHT VIOLATION WARNING: “Adamis Pharmaceuticals Corp (ADMP) Rating Reiterated by B. Riley” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/06/adamis-pharmaceuticals-corp-admp-rating-reiterated-by-b-riley.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADMP. Axiom International Investors LLC DE purchased a new position in Adamis Pharmaceuticals Corp in the first quarter worth about $1,698,000. IFP Advisors Inc grew its position in Adamis Pharmaceuticals Corp by 2,245.6% in the second quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock worth $179,000 after acquiring an additional 32,965 shares in the last quarter. Sterling Global Strategies LLC grew its position in Adamis Pharmaceuticals Corp by 66.5% in the second quarter. Sterling Global Strategies LLC now owns 70,934 shares of the specialty pharmaceutical company’s stock worth $369,000 after acquiring an additional 28,334 shares in the last quarter. Leisure Capital Management grew its position in Adamis Pharmaceuticals Corp by 7.2% in the second quarter. Leisure Capital Management now owns 145,909 shares of the specialty pharmaceutical company’s stock worth $759,000 after acquiring an additional 9,832 shares in the last quarter. Finally, Wells Fargo & Company MN purchased a new position in Adamis Pharmaceuticals Corp in the second quarter worth about $169,000. Institutional investors own 10.14% of the company’s stock.

Adamis Pharmaceuticals Corp Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Receive News & Stock Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related stocks with our FREE daily email newsletter.